Paper
0
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Authors
Stefan Anker,Javed Butler
Gerasimos Filippatos,João Ferreira,Edimar Bocchi,Michael Böhm,Hans‐Peter Rocca,Dong‐Ju Choi,Vijay Chopra,Eduardo Chuquiure‐Valenzuela,Nadia Giannetti,Juan Gómez‐Mesa,Stefan Janssens,James Januzzi,José González‐Juanatey,Béla Merkely,Stephen Nicholls,Sergio Perrone,Ileana Piña,Piotr Ponikowski,Michele Senni,Domingo Pascual‐Figal,Jindřich Špinar,Iain Squire,Stefano Taddei,Hiroyuki Tsutsui,Subodh Verma,Dragoş Vinereanu,Jian Zhang,Peter Carson,Carolyn Lam,Nikolaus Marx,Cordula Zeller,Naveed Sattar,Waheed Jamal,Sven Schnaidt,Janet Schnee,Martina Brueckmann,Stuart Pocock,Faı̈ez Zannad,Milton Packer
+39 authors
,David SimPublished
Aug 27, 2021
Show more
Save
Tip0
TipSave
Abstract
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.